News Headlines Article

Would California spend $6.7 billion for hepatitis C drug?
San Francisco Chronicle

California could spend $6.7 billion if it provided Gilead Sciences’ $1,000-a-day hepatitis C drug to all Medi-Cal enrollees and prisoners with the disease, according to an analysis released Thursday by one of Gilead’s loudest critics.

And if all the states provided their stricken patients with Sovaldi and its accompanying medication, ribavirin, the cost to the nation’s taxpayers would total $55 billion.

Those estimates were released by the Express-Scripts Holding Co., the nation’s largest pharmacy benefits manager.